InMed Pharmaceuticals with Dr. Shane Johnson

0

InMed Pharmaceuticals with Dr. Shane Johnson

InMed Pharmaceuticals With Dr. Shane Johnson today on Concierge For Better Living With Doc Rob only on The Cannabis Radio. InMed Pharmaceuticals is a world leader in the development, manufacturing and marketing of rare cannabinoids. Together with our subsidiary, BayMedica, we have unparalleled cannabinoid manufacturing capabilities to serve an array of consumer markets, including pharmaceuticals, health and wellness. InMed is a clinical-stage company developing a pipeline of rare therapeutic cannabinoids and dedicated to providing new treatment alternatives to patients who may benefit from cannabinoid-based pharmaceutical drugs. InMed’s subsidiary, BayMedica, produces a portfolio of rare cannabinoids as raw ingredients for your health and wellness products. They have engineered bioidentical cannabinoids with high purity and consistency, and are THC-free. InMed currently manufactures the rare minor cannabinoids cannabidivarin (CBDV), cannabichromene (CBC) and cannabicitran (CBT) which are available for wholesale purchase. They have begun production of Tetrahydrocannabivarin (THCV), with plans to have this highly sought after minor cannabinoid soon ready to be included in a wide variety of health and wellness products.


InMed’s rare cannabinoids are used in a wide range of uses, from pharmaceutical development to wholesale sales to the consumer health and wellness sector. Their pharmaceutical programs include a Phase 2 clinical program in dermatology and a preclinical program in glaucoma. Our division, BayMedica, is the leading producer of wholesale CBC cannabinoids (cannabichromene) for the consumer health and wellness industry. In addition to CBC, InMed has launched sales of cannabidivarin (CBDV) and cannabicitran (CBT) and has begun commercial scale production of soon to be launched tetrahydrocannabivarin (THCV). Our portfolio also includes a growing library of patentable rare cannabinoid analogs for development.

Share.

Comments are closed.